Farmalatam Holding Inc.
Category B projects have potential environmental and/or social impacts and risks that are less adverse than those of a Category A and which are generally limited to the project site, largely reversible and can be mitigated via measures that are readily available and feasible to implement in the context of the operation.
Projected date at which a project will be put forward for the Board of Executive Directors’ approval.
Projected board date
Vera Fabbri, Pablo Marcelo
USD $ 8,000,000
Project scope and objective
IDB Invest is considering a capital investment of up to US$8 million in Farmalatam Holding Inc. ("Farmalatam” or the "Company"). Farmalatam is a leading home healthcare technology platform in Latin America that provides comprehensive healthcare solutions to patients. Farmalatam is a 100% digital pharmacy with no physical stores, which distributes pharmaceutical products. In addition, it provides home health and telemedicine services through its digital platform “CARE24”. Since its incorporation in 2014, the Company has developed a user and partnership base, demonstrating its readiness to move on to the next phase and achieve greater scales. Farmalatam currently operates in Colombia, Mexico, and Peru.
The capital round will allow Farmalatam to support its growth plan as follows: (i) finance current operations to support expected growth through investments in marketing, information technology, and human resources, among others; (ii) finance strategic acquisitions of related businesses in Latin America; and (iii) promote its regional expansion.
This investment will require the implementation of reforms in order to strengthen its policies and controls in its operation - particularly to ensure equitable prices in the context of the health crisis and thereafter. Furthermore, Farmalatam is committed to implementing improvements in corporate governance.
The objectives of investing in Farmalatam are (i) to help support the growth of the digital economy and stimulate productivity in the pharmaceutical sector through a disruptive, technology-enabled business model with sizable addressable markets; (ii) to contribute to reducing the cost of medicine and expand access to cheaper costs in target markets; and (iii) to support access to medical services and home treatments.
For inquiries, comments and information requests about the projectRequest information
Alternatively, you may also use the following contact information:
José Joaquín Mora Hernández
(57 1) 4926360
IDB Invest Contact
1350 New York Ave NW, Washington, DC 20005